Fmr LLC Grows Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

FMR LLC raised its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 6.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,881,912 shares of the company's stock after buying an additional 698,434 shares during the quarter. FMR LLC owned about 15.00% of Viridian Therapeutics worth $227,776,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Loomis Sayles & Co. L P bought a new position in shares of Viridian Therapeutics in the 4th quarter valued at about $26,845,000. Victory Capital Management Inc. bought a new position in Viridian Therapeutics during the 4th quarter valued at about $7,868,000. Lord Abbett & CO. LLC bought a new stake in Viridian Therapeutics in the third quarter worth about $8,917,000. Raymond James Financial Inc. bought a new position in shares of Viridian Therapeutics during the fourth quarter valued at approximately $6,015,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock worth $9,108,000 after acquiring an additional 274,641 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wells Fargo & Company reissued an "equal weight" rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Viridian Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Price Performance

NASDAQ VRDN traded up $0.06 during trading hours on Thursday, hitting $12.71. 257,441 shares of the company's stock traded hands, compared to its average volume of 1,198,197. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The firm's 50-day moving average is $14.74 and its 200-day moving average is $18.76. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20. The company has a market capitalization of $1.04 billion, a PE ratio of -2.97 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.